Celmatix Names Mark Adams as Chief Information Officer

Seasoned executive with deep experience in genomics, cloud computing, and data analytics to lead efforts to scale informatics systems

NEW YORK--(BUSINESS WIRE)-- Celmatix, a personalized medicine company focused on fertility and women’s health, today announced it has named Mark Adams, PhD, as its first Chief Information Officer. In this position, Dr. Adams will play a critical role on the leadership team, scaling the company’s bioinformatics and data analytics operations to support both the upcoming commercial launch of its genetic test and ongoing growth of the company's flagship SaaS platform, Polaris.

Dr. Adams is a pioneer in the genomics space, having led some of the earliest commercial bioinformatics efforts to explore and use genomic data and information while at companies such as Variagenics and Incyte. While at Variagenics, he worked to build the company’s first informatics pipeline, supporting high-throughput SNP genomics. He joins Celmatix from Good Start Genetics, a leading carrier screening company, where he served as Chief Information Officer. Prior, he was with Bridgewater Associates, Ltd., where he developed unique data warehousing and machine learning approaches to support the world’s largest hedge fund. He was previously with Booz Allen Hamilton, where he built a leading biomedical informatics consulting practice focused on clients in the commercial, government, and nonprofit markets.

“Dr. Adams’s unique background in both bioinformatics and data analytics made him uniquely qualified for this important role at Celmatix,” explained Celmatix founder and CEO Dr. Piraye Yurttas Beim. She continued, “His rich background in the development and deployment of large-scale software in the bioinformatics community, as well as his expertise building communities comprised of academic, industry, and government partners to address healthcare issues are invaluable for Celmatix in our next phase of growth. We’re thrilled to have his experience and enthusiasm on our executive team.”

“I am very excited to join Celmatix, and be able to contribute to its mission of enabling more effective and efficient treatments for infertility,” Dr. Adams commented. “I have always been drawn to mission-driven organizations, and I believe that I have found one here. Working with the committed, talented, and creative community here at Celmatix will be both fulfilling and fun.”

Dr. Adams received his undergraduate degree from Oberlin College and his Ph.D. from Baylor College of Medicine. He currently lives in Connecticut with his wife and two teenage girls.

About CelmatixCelmatix is a personalized medicine company that uses big data and predictive analytics to help individuals who are struggling to have a baby make informed decisions. Founded in 2009 and based in New York City, Celmatix is disrupting the way women approach their lifelong fertility journey by empowering them through science and technology. The company’s flagship product, Polaris, is in use at top fertility clinics across the country and is the world’s first analytics platform for optimizing fertility. Celmatix also has an active research and development program dedicated to decoding the genetic basis of fertility potential. For more information, visit www.celmatix.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160901005421/en/

for Celmatix
Britta Franson, 310-591-7207
[email protected]

Source: Celmatix

You May Also Be Interested In

• HP Inc. (HPQ) Climbs Following Stake by Greenlight Capital
• Share Buyback Transaction Details April 18 – April 24, 2024
• Digitalist Group Plc’s Business Review, 1 January – 31 March 2024